Phase I/II study of the LAG-3 inhibitor ieramilimab (LAG525) ± anti-PD-1 spartalizumab (PDR001) in patients with advanced malignancies

Schöffski, P., Tan, D. S. W., Martín, M., Ochoa-de-Olza, M., Sarantopoulos, J., Carvajal, R. D., Kyi, C., Esaki, T., Prawira, A., Akerley, W., De Braud, F., Hui, R., Zhang, T., Soo, R. A., Maur, M., Weickhardt, A., Krauss, J., Deschler-Baier, B., Lau, A., … Hong, D. S. (2022). Phase I/II study of the LAG-3 inhibitor ieramilimab (LAG525) ± anti-PD-1 spartalizumab (PDR001) in patients with advanced malignancies. Journal for ImmunoTherapy of Cancer, 10(2), e003776. https://doi.org/10.1136/jitc-2021-003776
Authors:
Patrick Schöffski
Daniel Shao-Weng Tan
Miguel Martín
Maria Ochoa de Olza
John Sarantopoulos
Richard D. Carvajal
Chrisann Kyi
Taito Esaki
Amy Prawira
Wallace Akerley
Filippo de Braud
Rina Hui
Tian Zhang
Ross A. Soo
Michela Maur
Andrew Weickhardt
Jürgen Krauß
Barbara Deschler-Baier
Allen S. Lau
Tanay S. Samant
Tyler A. Longmire
Niladri Roy Chowdhury
Catherine A. Sabatos‐Peyton
Nidhi Patel
Radha Ramesh
Tiancen Hu
Ana Carion
Daniel Gusenleitner
Padmaja Yerramilli-Rao
Vasileios Askoxylakis
Eunice L. Kwak
David S. Hong
Affiliated Authors:
Richard D. Carvajal
Columbia Affiliation:
Subjects:
Antibodies, Monoclonal, Humanized (MeSH)
Immune Checkpoint Inhibitors (MeSH)
Immunotherapy (MeSH)
Neoplasms (MeSH)
Cancer Immunotherapy (OpenAlex Topic)
Chimeric Antigen Receptor T Cell Therapy (OpenAlex Topic)
Neuroblastoma Research and Treatment (OpenAlex Topic)
Author Keywords:
immunotherapy
drug therapy
combination
elink
Publication Type:
Article
Unique ID:
10.1136/jitc-2021-003776
PMID:
35217575
DOI:
10.1136/jitc-2021-003776
Journal:
Journal for ImmunoTherapy of Cancer
Publication Date:
Data Source:
OpenAlex
Source Link:
View OpenAlex Record
View PubMed Record
View Scopus Record
View Web of Science Record

Record Created: